Medipattern Reports Highlights and Results for Q3 2012
(firmenpresse) - TORONTO, ONTARIO -- (Marketwire) -- 05/30/12 -- The Medipattern Corporation (TSX VENTURE: MKI) ("Medipattern" or the "Company") is pleased to report third quarter highlights and results from the Company's 2012 financial year, to March 31, 2012.
"Key milestones were met in the vascular product line during the third quarter. Daily clinical use in the diagnostic imaging market of Visualize:Vascular is confirming that the product is medically beneficial, easy to use and cost effective in practice. We are extremely pleased with the growing acceptance of the product and the continued ramp up in installations and scanning volumes," stated Jeff Collins, CEO of Medipattern. "Our increased exposure to the vascular market and cardiologists has created new opportunities for Medipattern, like the recently announced MyTrak Personal Health Solutions product, which addresses external patient monitoring requirements that are not being adequately addressed in the market. We expect that the new product we are developing utilizing MyTrak Health Solutions proprietary technology will be readily accepted and fill a significant void in the patient wellness space, as well as create a significant new revenue stream for Medipattern. The potential for the Company's product offering in both the diagnostic imaging market and the patient wellness market is very strong and the Company is positioned well in both markets."
For further details concerning Medipattern's results, please see the Company's filings on SEDAR ().
About the Medipattern Corporation:
Medipattern® is a pioneer in the development of imaging software solutions that help medical practitioners to better understand lesions and critical anatomy. Medipattern uses its Cadenza™ technology to process images, finding the salient region of interest and presenting them in 2D and 3D formats that enhance the reader's perception. For more information, please visit the Company's website: .
Medipattern® and B-CAD® are registered marks of The Medipattern Corporation. Visualize:Vascular™ is a trademark of the Medipattern Corporation.
Forward-looking statements
This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates", "believes", "estimates", "expects", "plans", "intends", "potential", and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings (posted at ). In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
The Medipattern Corporation
Jeff Collins
CEO
(416) 744-0009 ext. 224
Spinnaker Capital Markets Inc.
Kevin O'Connor
(416) 962-3300 ext. 226
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 30.05.2012 - 22:46 Uhr
Sprache: Deutsch
News-ID 151552
Anzahl Zeichen: 0
contact information:
Town:
TORONTO, ONTARIO
Kategorie:
Software
Diese Pressemitteilung wurde bisher 315 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medipattern Reports Highlights and Results for Q3 2012"
steht unter der journalistisch-redaktionellen Verantwortung von
The Medipattern Corporation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
